Nama's AI scorecard currently rates Avantor Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AVTR's P/E ratio?

Avantor trades at a trailing price-to-earnings ratio of 18.9.

When does AVTR report earnings?

Avantor's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.22.

What is the AVTR price target?

The median analyst price target from 13 analysts is $17.00, with a range of $16.00 – $19.00.

Is AVTR Shariah compliant?

Nama's AAOIFI-style screen reads Avantor as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Avantor (AVTR)

Healthcare · Medical Instruments Supplies · NYSE

Avantor (AVTR) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $10.48B, a trailing price-to-earnings ratio of 18.9 and a free-cash-flow yield of 4.7%. Over the most recent reported fiscal year, revenue declined 3.4% and free cash flow per share fell 28.3%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +35.6% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-63.6%

How far the last close sits under the highest price of the past five years.

Market cap	$10.48B
Trailing P/E	18.9
Price / book	1.8
Price / sales	1.6
FCF yield	4.7%
Dividend yield	—
Gross margin	31.6%
Operating margin	7.4%
Net margin	5.1%
Revenue growth (YoY)	-3.4%
Revenue growth (3-yr annual)	-4.5%
EPS growth (YoY)	-9.0%
FCF/share growth (YoY)	-28.3%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

AVTR earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate $0.22). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$0.22	$0.21	+4.8%	$1.70B
Q2 2026	Jul 29, 2026	$0.21	$0.19	+10.5%	$1.69B
Q1 2026	Apr 29, 2026	$0.17	$0.16	+6.2%	$1.58B
Q4 2025	Feb 11, 2026	$0.22	$0.22	+0.0%	$1.66B

AVTR analyst price target

Median target $17.00 from 13 analysts, ranging $16.00 – $19.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live AVTR data on Nama Insights →

Recent Congressional trades

Avantor trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Sep 12, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Sep 12, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Aug 14, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Daniel Goldman	House	Sell	$1,001 - $15,000	Aug 13, 2023

AVTR FAQ

Is AVTR a buy?: Nama's AI scorecard currently rates Avantor Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AVTR's P/E ratio?: Avantor trades at a trailing price-to-earnings ratio of 18.9.
When does AVTR report earnings?: Avantor's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.22.
What is the AVTR price target?: The median analyst price target from 13 analysts is $17.00, with a range of $16.00 – $19.00.
Is AVTR Shariah compliant?: Nama's AAOIFI-style screen reads Avantor as Not Shariah Compliant. At least one of the three ratios or the industry test failed.